Drug Profile
Research programme: metallo beta lactamase inhibitors - Infex Therapeutics/Medivir
Alternative Names: MBLI - Infex Therapeutics/MedivirLatest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Infex Therapeutics
- Class Antibacterials
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gram-negative infections
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 18 Aug 2023 INFEX and Tango Therapeutics plans a phase I trial for Gram-negative infections in 2024
- 20 Jan 2023 Preclinical development is ongoing in United kingdom (Infex Therapeutics pipeline, January 2023)
- 20 Jan 2023 Metallo beta lactamase inhibitors - Infex Therapeutics/Medivir is available for licensing as of 30 Jun 2020. https://www.amrcentre.com/partnering/